| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | NMB; HGFIN |
| Entrez GeneID | 10457 |
| clone | 7C10E5 |
| WB Predicted band size | 64kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human GPNMB (AA: 31-260) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4篇关于GPNMB抗体的代表性文献的简要总结：
1. **文献名称**：*"GPNMB-targeted antibody-drug conjugate induces anti-tumor activity in melanoma"*
**作者**：Tomiyama et al.
**摘要**：研究开发了一种靶向GPNMB的抗体药物偶联物(CR011-vcMMAE)，在黑色素瘤模型中显示显著抑制肿瘤生长，并揭示了GPNMB作为治疗靶点的潜力。
2. **文献名称**：*"Therapeutic targeting of GPNMB in triple-negative breast cancer"*
**作者**：Rose et al.
**摘要**：通过单克隆抗体靶向GPNMB，抑制三阴性乳腺癌细胞的增殖和转移，机制涉及阻断GPNMB介促的PI3K/Akt信号通路，支持其临床转化价值。
3. **文献名称**：*"GPNMB antibody attenuates renal fibrosis by modulating macrophage polarization"*
**作者**：Tsubaki et al.
**摘要**：抗GPNMB抗体通过调控巨噬细胞向抗炎表型转化，减轻小鼠肾纤维化损伤，表明其在纤维化疾病中的治疗作用。
4. **文献名称**：*"Anti-GPNMB antibody enhances temozolomide sensitivity in glioblastoma"*
**作者**：Yamamoto et al.
**摘要**：靶向GPNMB的抗体可增强胶质母细胞瘤对替莫唑胺的化疗敏感性，机制与抑制DNA修复通路相关，为联合治疗提供新策略。
如需具体文章或补充信息，可进一步提供方向或关键词!
**Background of GPNMB Antibodies**
GPNMB (Glycoprotein Non-Metastatic Melanoma Protein B), also known as HGFIN or DC-HIL, is a type I transmembrane protein encoded by the *GPNMB* gene. Structurally, it contains an extracellular domain with homology to pigment epithelium-derived factor, a single transmembrane region, and a short cytoplasmic tail. GPNMB is implicated in diverse cellular processes, including adhesion, differentiation, and signaling, often via interactions with integrins or other receptors. Its expression is upregulated in certain cancers, such as melanoma, glioblastoma, and breast cancer, where it exhibits dual roles—suppressing metastasis in melanoma but promoting tumor progression in other contexts through pro-inflammatory or pro-survival mechanisms.
GPNMB is also linked to non-cancer pathologies, including neurodegenerative diseases (e.g., ALS, Parkinson’s) and atherosclerosis, highlighting its role in inflammation and tissue repair. Antibodies targeting GPNMB serve as critical tools for research, enabling detection of its expression in tissues or cells. Therapeutically, GPNMB-directed antibody-drug conjugates (ADCs), like glembatumumab vedotin, have been explored to selectively deliver cytotoxic agents to GPNMB-overexpressing tumors. Other strategies include monoclonal antibodies to block pathogenic interactions (e.g., in autoimmune disorders) or CAR-T cell therapies.
While clinical trials for GPNMB-targeted ADCs show mixed outcomes, they underscore its potential as a biomarker and therapeutic target. Challenges remain in optimizing specificity, managing on-target toxicity, and understanding context-dependent roles of GPNMB in disease. Ongoing research aims to clarify its mechanistic contributions and refine therapeutic strategies.
×
